Position in NVAX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$1,344,557
+$627,309 QoQ
Shares Held
165,179
+45.1% QoQ
Ownership
0.100%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in NVAX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,344,557 | 165,179 | Shares | Sole | 2026-05-08 | |
| 2025-06-30 | $717,248 | 113,849 | Shares | Sole | 2025-07-22 | |
| 2024-06-30 | $253,782 | 20,046 | Shares | Sole | 2024-08-15 | |
| 2023-09-30 | $87,053 | 12,024 | Shares | Sole | 2023-11-15 | |
| 2023-03-31 | $80,117 | 11,561 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $249,999 | 24,319 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $427,099 | 23,467 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $398,004 | 5,404 | Shares | Sole | 2022-05-11 | |
| 2021-12-31 | $318,187 | 2,224 | Shares | Sole | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||